How are you interpreting the early RASolute 302 trial findings (daraxonrasib) in metastatic PDAC?

This is an extremely exciting time in pancreatic cancer treatment! I note that PDAC/KRAS G12D has a plenary this year at ASCO's Annual Meeting. The company has also put out a press release stating this is a positive study against chemotherapy with a doubling of overall survival. Of course, we all wa...